Global Antimicrobial Susceptibility Testing Market

Antimicrobial Susceptibility Testing Comprehensive Study by Type (Antibacterial Susceptibility Testing, Antifungal Susceptibility Testing, Antiparasitic Susceptibility Testing, Other Susceptibility Testing), Application (Clinical Diagnostics, Drug Discovery and Development, Epidemiology, Other Applications), Product (Manual Antimicrobial Susceptibility Testing Products, Automated Laboratory Instruments, Culture and Growth Media, Consumables), Method (Disk Diffusion, Automated Ast, Genotypic Methods, Dilution, Etest), End User (Diagnostic Centers and Hospitals, Pharmaceutical and Biotechnology Companies, Contract Research Organizations (CROs), Research and Academic Institutes) Players and Region - Global Market Outlook to 2028

Antimicrobial Susceptibility Testing Market by XX Submarkets | Forecast Years 2023-2028  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Market Overview:
Antimicrobial susceptibility testing is a procedure used to determine which antibiotics a specific organism or group of organisms are susceptible to. The antimicrobial susceptibility testing market is expected to grow in the future due to the increasing prevalence of infectious diseases across the globe and government initiatives towards improving the detection and control of antimicrobial-resistant species.



AttributesDetails
Study Period2018-2028
Base Year2022
Forecast Period2023-2028
Historical Period2018-2022
UnitValue (USD Million)
Key Companies ProfiledBiomérieux (France), Danaher (United States), BD (United States), Thermo Fisher (United States), Hi-Media (India), Bio-Rad (United States), Merlin (Germany), Liofilchem (Italy), Accelerate (United States), Alifax (Italy), Creative Diagnostics (United States) and Merck Group (Germany)
Customization ScopeAvail customization with purchase of this report. Add or modify country, region or narrow down segments in the final scope subject to feasibility


AMA Research follows a focused and realistic research framework that provides the ability to study the crucial market dynamics of major and emerging geographies across the world. Moreover, an in-depth assessment is mostly conducted by our analysts on geographical regions to provide clients and businesses the opportunity to dominate in niche markets and expand in emerging markets across the globe. This market research study also showcases the spontaneously changing Players landscape impacting the growth of the market. Furthermore, our market researchers extensively analyze the products and services offered by multiple players competing to increase their market share and presence.

Key Players of Antimicrobial Susceptibility Testing Market Study:
Biomérieux (France), Danaher (United States), BD (United States), Thermo Fisher (United States), Hi-Media (India), Bio-Rad (United States), Merlin (Germany), Liofilchem (Italy), Accelerate (United States), Alifax (Italy), Creative Diagnostics (United States) and Merck Group (Germany)

Antimicrobial Susceptibility Testing Market Segment Analysis
ScopeSub-Segments
Application / End UserClinical Diagnostics, Drug Discovery and Development, Epidemiology and Other Applications
TypeAntibacterial Susceptibility Testing, Antifungal Susceptibility Testing, Antiparasitic Susceptibility Testing and Other Susceptibility Testing
ProductManual Antimicrobial Susceptibility Testing Products,Automated Laboratory Instruments,Culture and Growth Media,Consumables
MethodDisk Diffusion,Automated Ast,Genotypic Methods,Dilution,Etest
End UserDiagnostic Centers and Hospitals,Pharmaceutical and Biotechnology Companies,Contract Research Organizations (CROs),Research and Academic Institutes


Influencing Trend:
Availability of Automated Antimicrobial Susceptibility Testing Systems

Market Growth Drivers:
Rising Prevalence of Infectious Diseases and Technological Advancements Towards the Development of Rapid Antimicrobial Susceptibility Testing Methods

Challenges:
High Cost of Automated Antimicrobial Susceptibility Testing Systems and Lack of Coordination Between Regulatory Bodies, Clinical Laboratories, and Ast Manufacturers

Restraints:
Unfavorable Reimbursement Scenario

Opportunities:
Rising Demand From Emerging Country and Increasing Funding and Public-Private Investments

Some of the other players that are also part of study are Bioanalyse (Turkey), Synbiosis (United Kingdom) and Zhuhai Dl Biotech (China). The Global Antimicrobial Susceptibility Testing market is gaining huge competition due to involvement of United States companies that constantly invest in research & development to meet market expectation with new innovation.

Latest Industry Highlights:
In April 2020, the antimicrobials Cefiderocol and imipenem/relebactam are now available on the U.S. Food and Drug Administration (FDA) approved microbroth dilution susceptibility plates, expanding testing options for microbiology laboratories, and providing the quantitative susceptibility results clinicians need to make treatment decisions for serious Gram-negative infections.
In April 2022, Biomérieux acquired Specific Diagnostics, a privately held U.S. based company that has developed a rapid antimicrobial susceptibility test (AST) system that delivers phenotypic AST directly from positive blood cultures. This acquisition helped company to expand its presence in antimicrobial susceptibility testing market


Research Methodology:
The top-down and bottom-up approaches are used to estimate and validate the size of the Global Antimicrobial Susceptibility Testing market.
In order to reach an exhaustive list of functional and relevant players, various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep into important geographies by players, and a thorough validation test is conducted to reach the most relevant players for survey in Antimicrobial Susceptibility Testing market.
Identification of total players or companies operating in the global market which is further concentrated to fewer or most impacting players which are considered under the report’s scope. In order to make a priority list sorting is done based on revenue generated based on the latest reporting with the help of paid databases such as Factiva, Bloomberg, etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment by targeting key target audience that includes Antimicrobial Susceptibility Testing Providers, Research Professionals, Emerging Companies, Government Body & Associations and End-user.

This helps us to gather the data for the players’ revenue, operating cycle and expense, profit along with product or service growth, etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that include Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, Annual reports, press releases etc.

Report Objectives / Segmentation Covered

By Type
  • Antibacterial Susceptibility Testing
  • Antifungal Susceptibility Testing
  • Antiparasitic Susceptibility Testing
  • Other Susceptibility Testing
By Application
  • Clinical Diagnostics
  • Drug Discovery and Development
  • Epidemiology
  • Other Applications
By Product
  • Manual Antimicrobial Susceptibility Testing Products
  • Automated Laboratory Instruments
  • Culture and Growth Media
  • Consumables

By Method
  • Disk Diffusion
  • Automated Ast
  • Genotypic Methods
  • Dilution
  • Etest

By End User
  • Diagnostic Centers and Hospitals
  • Pharmaceutical and Biotechnology Companies
  • Contract Research Organizations (CROs)
  • Research and Academic Institutes

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Rising Prevalence of Infectious Diseases
      • 3.2.2. Technological Advancements Towards the Development of Rapid Antimicrobial Susceptibility Testing Methods
    • 3.3. Market Challenges
      • 3.3.1. High Cost of Automated Antimicrobial Susceptibility Testing Systems
      • 3.3.2. Lack of Coordination Between Regulatory Bodies, Clinical Laboratories, and Ast Manufacturers
    • 3.4. Market Trends
      • 3.4.1. Availability of Automated Antimicrobial Susceptibility Testing Systems
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Antimicrobial Susceptibility Testing, by Type, Application, Product, Method, End User and Region (value) (2017-2022)
    • 5.1. Introduction
    • 5.2. Global Antimicrobial Susceptibility Testing (Value)
      • 5.2.1. Global Antimicrobial Susceptibility Testing by: Type (Value)
        • 5.2.1.1. Antibacterial Susceptibility Testing
        • 5.2.1.2. Antifungal Susceptibility Testing
        • 5.2.1.3. Antiparasitic Susceptibility Testing
        • 5.2.1.4. Other Susceptibility Testing
      • 5.2.2. Global Antimicrobial Susceptibility Testing by: Application (Value)
        • 5.2.2.1. Clinical Diagnostics
        • 5.2.2.2. Drug Discovery and Development
        • 5.2.2.3. Epidemiology
        • 5.2.2.4. Other Applications
      • 5.2.3. Global Antimicrobial Susceptibility Testing by: Product (Value)
        • 5.2.3.1. Manual Antimicrobial Susceptibility Testing Products
        • 5.2.3.2. Automated Laboratory Instruments
        • 5.2.3.3. Culture and Growth Media
        • 5.2.3.4. Consumables
      • 5.2.4. Global Antimicrobial Susceptibility Testing by: Method (Value)
        • 5.2.4.1. Disk Diffusion
        • 5.2.4.2. Automated Ast
        • 5.2.4.3. Genotypic Methods
        • 5.2.4.4. Dilution
        • 5.2.4.5. Etest
      • 5.2.5. Global Antimicrobial Susceptibility Testing by: End User (Value)
        • 5.2.5.1. Diagnostic Centers and Hospitals
        • 5.2.5.2. Pharmaceutical and Biotechnology Companies
        • 5.2.5.3. Contract Research Organizations (CROs)
        • 5.2.5.4. Research and Academic Institutes
      • 5.2.6. Global Antimicrobial Susceptibility Testing Region
        • 5.2.6.1. South America
          • 5.2.6.1.1. Brazil
          • 5.2.6.1.2. Argentina
          • 5.2.6.1.3. Rest of South America
        • 5.2.6.2. Asia Pacific
          • 5.2.6.2.1. China
          • 5.2.6.2.2. Japan
          • 5.2.6.2.3. India
          • 5.2.6.2.4. South Korea
          • 5.2.6.2.5. Taiwan
          • 5.2.6.2.6. Australia
          • 5.2.6.2.7. Rest of Asia-Pacific
        • 5.2.6.3. Europe
          • 5.2.6.3.1. Germany
          • 5.2.6.3.2. France
          • 5.2.6.3.3. Italy
          • 5.2.6.3.4. United Kingdom
          • 5.2.6.3.5. Netherlands
          • 5.2.6.3.6. Rest of Europe
        • 5.2.6.4. MEA
          • 5.2.6.4.1. Middle East
          • 5.2.6.4.2. Africa
        • 5.2.6.5. North America
          • 5.2.6.5.1. United States
          • 5.2.6.5.2. Canada
          • 5.2.6.5.3. Mexico
  • 6. Antimicrobial Susceptibility Testing: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2022)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Biomérieux (France)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Danaher (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. BD (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Thermo Fisher (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Hi-Media (India)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Bio-Rad (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Merlin (Germany)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Liofilchem (Italy)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Accelerate (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Alifax (Italy)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Creative Diagnostics (United States)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
      • 6.4.12. Merck Group (Germany)
        • 6.4.12.1. Business Overview
        • 6.4.12.2. Products/Services Offerings
        • 6.4.12.3. Financial Analysis
        • 6.4.12.4. SWOT Analysis
  • 7. Global Antimicrobial Susceptibility Testing Sale, by Type, Application, Product, Method, End User and Region (value) (2023-2028)
    • 7.1. Introduction
    • 7.2. Global Antimicrobial Susceptibility Testing (Value)
      • 7.2.1. Global Antimicrobial Susceptibility Testing by: Type (Value)
        • 7.2.1.1. Antibacterial Susceptibility Testing
        • 7.2.1.2. Antifungal Susceptibility Testing
        • 7.2.1.3. Antiparasitic Susceptibility Testing
        • 7.2.1.4. Other Susceptibility Testing
      • 7.2.2. Global Antimicrobial Susceptibility Testing by: Application (Value)
        • 7.2.2.1. Clinical Diagnostics
        • 7.2.2.2. Drug Discovery and Development
        • 7.2.2.3. Epidemiology
        • 7.2.2.4. Other Applications
      • 7.2.3. Global Antimicrobial Susceptibility Testing by: Product (Value)
        • 7.2.3.1. Manual Antimicrobial Susceptibility Testing Products
        • 7.2.3.2. Automated Laboratory Instruments
        • 7.2.3.3. Culture and Growth Media
        • 7.2.3.4. Consumables
      • 7.2.4. Global Antimicrobial Susceptibility Testing by: Method (Value)
        • 7.2.4.1. Disk Diffusion
        • 7.2.4.2. Automated Ast
        • 7.2.4.3. Genotypic Methods
        • 7.2.4.4. Dilution
        • 7.2.4.5. Etest
      • 7.2.5. Global Antimicrobial Susceptibility Testing by: End User (Value)
        • 7.2.5.1. Diagnostic Centers and Hospitals
        • 7.2.5.2. Pharmaceutical and Biotechnology Companies
        • 7.2.5.3. Contract Research Organizations (CROs)
        • 7.2.5.4. Research and Academic Institutes
      • 7.2.6. Global Antimicrobial Susceptibility Testing Region
        • 7.2.6.1. South America
          • 7.2.6.1.1. Brazil
          • 7.2.6.1.2. Argentina
          • 7.2.6.1.3. Rest of South America
        • 7.2.6.2. Asia Pacific
          • 7.2.6.2.1. China
          • 7.2.6.2.2. Japan
          • 7.2.6.2.3. India
          • 7.2.6.2.4. South Korea
          • 7.2.6.2.5. Taiwan
          • 7.2.6.2.6. Australia
          • 7.2.6.2.7. Rest of Asia-Pacific
        • 7.2.6.3. Europe
          • 7.2.6.3.1. Germany
          • 7.2.6.3.2. France
          • 7.2.6.3.3. Italy
          • 7.2.6.3.4. United Kingdom
          • 7.2.6.3.5. Netherlands
          • 7.2.6.3.6. Rest of Europe
        • 7.2.6.4. MEA
          • 7.2.6.4.1. Middle East
          • 7.2.6.4.2. Africa
        • 7.2.6.5. North America
          • 7.2.6.5.1. United States
          • 7.2.6.5.2. Canada
          • 7.2.6.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Antimicrobial Susceptibility Testing: by Type(USD Million)
  • Table 2. Antimicrobial Susceptibility Testing Antibacterial Susceptibility Testing , by Region USD Million (2017-2022)
  • Table 3. Antimicrobial Susceptibility Testing Antifungal Susceptibility Testing , by Region USD Million (2017-2022)
  • Table 4. Antimicrobial Susceptibility Testing Antiparasitic Susceptibility Testing , by Region USD Million (2017-2022)
  • Table 5. Antimicrobial Susceptibility Testing Other Susceptibility Testing , by Region USD Million (2017-2022)
  • Table 6. Antimicrobial Susceptibility Testing: by Application(USD Million)
  • Table 7. Antimicrobial Susceptibility Testing Clinical Diagnostics , by Region USD Million (2017-2022)
  • Table 8. Antimicrobial Susceptibility Testing Drug Discovery and Development , by Region USD Million (2017-2022)
  • Table 9. Antimicrobial Susceptibility Testing Epidemiology , by Region USD Million (2017-2022)
  • Table 10. Antimicrobial Susceptibility Testing Other Applications , by Region USD Million (2017-2022)
  • Table 11. Antimicrobial Susceptibility Testing: by Product(USD Million)
  • Table 12. Antimicrobial Susceptibility Testing Manual Antimicrobial Susceptibility Testing Products , by Region USD Million (2017-2022)
  • Table 13. Antimicrobial Susceptibility Testing Automated Laboratory Instruments , by Region USD Million (2017-2022)
  • Table 14. Antimicrobial Susceptibility Testing Culture and Growth Media , by Region USD Million (2017-2022)
  • Table 15. Antimicrobial Susceptibility Testing Consumables , by Region USD Million (2017-2022)
  • Table 16. Antimicrobial Susceptibility Testing: by Method(USD Million)
  • Table 17. Antimicrobial Susceptibility Testing Disk Diffusion , by Region USD Million (2017-2022)
  • Table 18. Antimicrobial Susceptibility Testing Automated Ast , by Region USD Million (2017-2022)
  • Table 19. Antimicrobial Susceptibility Testing Genotypic Methods , by Region USD Million (2017-2022)
  • Table 20. Antimicrobial Susceptibility Testing Dilution , by Region USD Million (2017-2022)
  • Table 21. Antimicrobial Susceptibility Testing Etest , by Region USD Million (2017-2022)
  • Table 22. Antimicrobial Susceptibility Testing: by End User(USD Million)
  • Table 23. Antimicrobial Susceptibility Testing Diagnostic Centers and Hospitals , by Region USD Million (2017-2022)
  • Table 24. Antimicrobial Susceptibility Testing Pharmaceutical and Biotechnology Companies , by Region USD Million (2017-2022)
  • Table 25. Antimicrobial Susceptibility Testing Contract Research Organizations (CROs) , by Region USD Million (2017-2022)
  • Table 26. Antimicrobial Susceptibility Testing Research and Academic Institutes , by Region USD Million (2017-2022)
  • Table 27. South America Antimicrobial Susceptibility Testing, by Country USD Million (2017-2022)
  • Table 28. South America Antimicrobial Susceptibility Testing, by Type USD Million (2017-2022)
  • Table 29. South America Antimicrobial Susceptibility Testing, by Application USD Million (2017-2022)
  • Table 30. South America Antimicrobial Susceptibility Testing, by Product USD Million (2017-2022)
  • Table 31. South America Antimicrobial Susceptibility Testing, by Method USD Million (2017-2022)
  • Table 32. South America Antimicrobial Susceptibility Testing, by End User USD Million (2017-2022)
  • Table 33. Brazil Antimicrobial Susceptibility Testing, by Type USD Million (2017-2022)
  • Table 34. Brazil Antimicrobial Susceptibility Testing, by Application USD Million (2017-2022)
  • Table 35. Brazil Antimicrobial Susceptibility Testing, by Product USD Million (2017-2022)
  • Table 36. Brazil Antimicrobial Susceptibility Testing, by Method USD Million (2017-2022)
  • Table 37. Brazil Antimicrobial Susceptibility Testing, by End User USD Million (2017-2022)
  • Table 38. Argentina Antimicrobial Susceptibility Testing, by Type USD Million (2017-2022)
  • Table 39. Argentina Antimicrobial Susceptibility Testing, by Application USD Million (2017-2022)
  • Table 40. Argentina Antimicrobial Susceptibility Testing, by Product USD Million (2017-2022)
  • Table 41. Argentina Antimicrobial Susceptibility Testing, by Method USD Million (2017-2022)
  • Table 42. Argentina Antimicrobial Susceptibility Testing, by End User USD Million (2017-2022)
  • Table 43. Rest of South America Antimicrobial Susceptibility Testing, by Type USD Million (2017-2022)
  • Table 44. Rest of South America Antimicrobial Susceptibility Testing, by Application USD Million (2017-2022)
  • Table 45. Rest of South America Antimicrobial Susceptibility Testing, by Product USD Million (2017-2022)
  • Table 46. Rest of South America Antimicrobial Susceptibility Testing, by Method USD Million (2017-2022)
  • Table 47. Rest of South America Antimicrobial Susceptibility Testing, by End User USD Million (2017-2022)
  • Table 48. Asia Pacific Antimicrobial Susceptibility Testing, by Country USD Million (2017-2022)
  • Table 49. Asia Pacific Antimicrobial Susceptibility Testing, by Type USD Million (2017-2022)
  • Table 50. Asia Pacific Antimicrobial Susceptibility Testing, by Application USD Million (2017-2022)
  • Table 51. Asia Pacific Antimicrobial Susceptibility Testing, by Product USD Million (2017-2022)
  • Table 52. Asia Pacific Antimicrobial Susceptibility Testing, by Method USD Million (2017-2022)
  • Table 53. Asia Pacific Antimicrobial Susceptibility Testing, by End User USD Million (2017-2022)
  • Table 54. China Antimicrobial Susceptibility Testing, by Type USD Million (2017-2022)
  • Table 55. China Antimicrobial Susceptibility Testing, by Application USD Million (2017-2022)
  • Table 56. China Antimicrobial Susceptibility Testing, by Product USD Million (2017-2022)
  • Table 57. China Antimicrobial Susceptibility Testing, by Method USD Million (2017-2022)
  • Table 58. China Antimicrobial Susceptibility Testing, by End User USD Million (2017-2022)
  • Table 59. Japan Antimicrobial Susceptibility Testing, by Type USD Million (2017-2022)
  • Table 60. Japan Antimicrobial Susceptibility Testing, by Application USD Million (2017-2022)
  • Table 61. Japan Antimicrobial Susceptibility Testing, by Product USD Million (2017-2022)
  • Table 62. Japan Antimicrobial Susceptibility Testing, by Method USD Million (2017-2022)
  • Table 63. Japan Antimicrobial Susceptibility Testing, by End User USD Million (2017-2022)
  • Table 64. India Antimicrobial Susceptibility Testing, by Type USD Million (2017-2022)
  • Table 65. India Antimicrobial Susceptibility Testing, by Application USD Million (2017-2022)
  • Table 66. India Antimicrobial Susceptibility Testing, by Product USD Million (2017-2022)
  • Table 67. India Antimicrobial Susceptibility Testing, by Method USD Million (2017-2022)
  • Table 68. India Antimicrobial Susceptibility Testing, by End User USD Million (2017-2022)
  • Table 69. South Korea Antimicrobial Susceptibility Testing, by Type USD Million (2017-2022)
  • Table 70. South Korea Antimicrobial Susceptibility Testing, by Application USD Million (2017-2022)
  • Table 71. South Korea Antimicrobial Susceptibility Testing, by Product USD Million (2017-2022)
  • Table 72. South Korea Antimicrobial Susceptibility Testing, by Method USD Million (2017-2022)
  • Table 73. South Korea Antimicrobial Susceptibility Testing, by End User USD Million (2017-2022)
  • Table 74. Taiwan Antimicrobial Susceptibility Testing, by Type USD Million (2017-2022)
  • Table 75. Taiwan Antimicrobial Susceptibility Testing, by Application USD Million (2017-2022)
  • Table 76. Taiwan Antimicrobial Susceptibility Testing, by Product USD Million (2017-2022)
  • Table 77. Taiwan Antimicrobial Susceptibility Testing, by Method USD Million (2017-2022)
  • Table 78. Taiwan Antimicrobial Susceptibility Testing, by End User USD Million (2017-2022)
  • Table 79. Australia Antimicrobial Susceptibility Testing, by Type USD Million (2017-2022)
  • Table 80. Australia Antimicrobial Susceptibility Testing, by Application USD Million (2017-2022)
  • Table 81. Australia Antimicrobial Susceptibility Testing, by Product USD Million (2017-2022)
  • Table 82. Australia Antimicrobial Susceptibility Testing, by Method USD Million (2017-2022)
  • Table 83. Australia Antimicrobial Susceptibility Testing, by End User USD Million (2017-2022)
  • Table 84. Rest of Asia-Pacific Antimicrobial Susceptibility Testing, by Type USD Million (2017-2022)
  • Table 85. Rest of Asia-Pacific Antimicrobial Susceptibility Testing, by Application USD Million (2017-2022)
  • Table 86. Rest of Asia-Pacific Antimicrobial Susceptibility Testing, by Product USD Million (2017-2022)
  • Table 87. Rest of Asia-Pacific Antimicrobial Susceptibility Testing, by Method USD Million (2017-2022)
  • Table 88. Rest of Asia-Pacific Antimicrobial Susceptibility Testing, by End User USD Million (2017-2022)
  • Table 89. Europe Antimicrobial Susceptibility Testing, by Country USD Million (2017-2022)
  • Table 90. Europe Antimicrobial Susceptibility Testing, by Type USD Million (2017-2022)
  • Table 91. Europe Antimicrobial Susceptibility Testing, by Application USD Million (2017-2022)
  • Table 92. Europe Antimicrobial Susceptibility Testing, by Product USD Million (2017-2022)
  • Table 93. Europe Antimicrobial Susceptibility Testing, by Method USD Million (2017-2022)
  • Table 94. Europe Antimicrobial Susceptibility Testing, by End User USD Million (2017-2022)
  • Table 95. Germany Antimicrobial Susceptibility Testing, by Type USD Million (2017-2022)
  • Table 96. Germany Antimicrobial Susceptibility Testing, by Application USD Million (2017-2022)
  • Table 97. Germany Antimicrobial Susceptibility Testing, by Product USD Million (2017-2022)
  • Table 98. Germany Antimicrobial Susceptibility Testing, by Method USD Million (2017-2022)
  • Table 99. Germany Antimicrobial Susceptibility Testing, by End User USD Million (2017-2022)
  • Table 100. France Antimicrobial Susceptibility Testing, by Type USD Million (2017-2022)
  • Table 101. France Antimicrobial Susceptibility Testing, by Application USD Million (2017-2022)
  • Table 102. France Antimicrobial Susceptibility Testing, by Product USD Million (2017-2022)
  • Table 103. France Antimicrobial Susceptibility Testing, by Method USD Million (2017-2022)
  • Table 104. France Antimicrobial Susceptibility Testing, by End User USD Million (2017-2022)
  • Table 105. Italy Antimicrobial Susceptibility Testing, by Type USD Million (2017-2022)
  • Table 106. Italy Antimicrobial Susceptibility Testing, by Application USD Million (2017-2022)
  • Table 107. Italy Antimicrobial Susceptibility Testing, by Product USD Million (2017-2022)
  • Table 108. Italy Antimicrobial Susceptibility Testing, by Method USD Million (2017-2022)
  • Table 109. Italy Antimicrobial Susceptibility Testing, by End User USD Million (2017-2022)
  • Table 110. United Kingdom Antimicrobial Susceptibility Testing, by Type USD Million (2017-2022)
  • Table 111. United Kingdom Antimicrobial Susceptibility Testing, by Application USD Million (2017-2022)
  • Table 112. United Kingdom Antimicrobial Susceptibility Testing, by Product USD Million (2017-2022)
  • Table 113. United Kingdom Antimicrobial Susceptibility Testing, by Method USD Million (2017-2022)
  • Table 114. United Kingdom Antimicrobial Susceptibility Testing, by End User USD Million (2017-2022)
  • Table 115. Netherlands Antimicrobial Susceptibility Testing, by Type USD Million (2017-2022)
  • Table 116. Netherlands Antimicrobial Susceptibility Testing, by Application USD Million (2017-2022)
  • Table 117. Netherlands Antimicrobial Susceptibility Testing, by Product USD Million (2017-2022)
  • Table 118. Netherlands Antimicrobial Susceptibility Testing, by Method USD Million (2017-2022)
  • Table 119. Netherlands Antimicrobial Susceptibility Testing, by End User USD Million (2017-2022)
  • Table 120. Rest of Europe Antimicrobial Susceptibility Testing, by Type USD Million (2017-2022)
  • Table 121. Rest of Europe Antimicrobial Susceptibility Testing, by Application USD Million (2017-2022)
  • Table 122. Rest of Europe Antimicrobial Susceptibility Testing, by Product USD Million (2017-2022)
  • Table 123. Rest of Europe Antimicrobial Susceptibility Testing, by Method USD Million (2017-2022)
  • Table 124. Rest of Europe Antimicrobial Susceptibility Testing, by End User USD Million (2017-2022)
  • Table 125. MEA Antimicrobial Susceptibility Testing, by Country USD Million (2017-2022)
  • Table 126. MEA Antimicrobial Susceptibility Testing, by Type USD Million (2017-2022)
  • Table 127. MEA Antimicrobial Susceptibility Testing, by Application USD Million (2017-2022)
  • Table 128. MEA Antimicrobial Susceptibility Testing, by Product USD Million (2017-2022)
  • Table 129. MEA Antimicrobial Susceptibility Testing, by Method USD Million (2017-2022)
  • Table 130. MEA Antimicrobial Susceptibility Testing, by End User USD Million (2017-2022)
  • Table 131. Middle East Antimicrobial Susceptibility Testing, by Type USD Million (2017-2022)
  • Table 132. Middle East Antimicrobial Susceptibility Testing, by Application USD Million (2017-2022)
  • Table 133. Middle East Antimicrobial Susceptibility Testing, by Product USD Million (2017-2022)
  • Table 134. Middle East Antimicrobial Susceptibility Testing, by Method USD Million (2017-2022)
  • Table 135. Middle East Antimicrobial Susceptibility Testing, by End User USD Million (2017-2022)
  • Table 136. Africa Antimicrobial Susceptibility Testing, by Type USD Million (2017-2022)
  • Table 137. Africa Antimicrobial Susceptibility Testing, by Application USD Million (2017-2022)
  • Table 138. Africa Antimicrobial Susceptibility Testing, by Product USD Million (2017-2022)
  • Table 139. Africa Antimicrobial Susceptibility Testing, by Method USD Million (2017-2022)
  • Table 140. Africa Antimicrobial Susceptibility Testing, by End User USD Million (2017-2022)
  • Table 141. North America Antimicrobial Susceptibility Testing, by Country USD Million (2017-2022)
  • Table 142. North America Antimicrobial Susceptibility Testing, by Type USD Million (2017-2022)
  • Table 143. North America Antimicrobial Susceptibility Testing, by Application USD Million (2017-2022)
  • Table 144. North America Antimicrobial Susceptibility Testing, by Product USD Million (2017-2022)
  • Table 145. North America Antimicrobial Susceptibility Testing, by Method USD Million (2017-2022)
  • Table 146. North America Antimicrobial Susceptibility Testing, by End User USD Million (2017-2022)
  • Table 147. United States Antimicrobial Susceptibility Testing, by Type USD Million (2017-2022)
  • Table 148. United States Antimicrobial Susceptibility Testing, by Application USD Million (2017-2022)
  • Table 149. United States Antimicrobial Susceptibility Testing, by Product USD Million (2017-2022)
  • Table 150. United States Antimicrobial Susceptibility Testing, by Method USD Million (2017-2022)
  • Table 151. United States Antimicrobial Susceptibility Testing, by End User USD Million (2017-2022)
  • Table 152. Canada Antimicrobial Susceptibility Testing, by Type USD Million (2017-2022)
  • Table 153. Canada Antimicrobial Susceptibility Testing, by Application USD Million (2017-2022)
  • Table 154. Canada Antimicrobial Susceptibility Testing, by Product USD Million (2017-2022)
  • Table 155. Canada Antimicrobial Susceptibility Testing, by Method USD Million (2017-2022)
  • Table 156. Canada Antimicrobial Susceptibility Testing, by End User USD Million (2017-2022)
  • Table 157. Mexico Antimicrobial Susceptibility Testing, by Type USD Million (2017-2022)
  • Table 158. Mexico Antimicrobial Susceptibility Testing, by Application USD Million (2017-2022)
  • Table 159. Mexico Antimicrobial Susceptibility Testing, by Product USD Million (2017-2022)
  • Table 160. Mexico Antimicrobial Susceptibility Testing, by Method USD Million (2017-2022)
  • Table 161. Mexico Antimicrobial Susceptibility Testing, by End User USD Million (2017-2022)
  • Table 162. Company Basic Information, Sales Area and Its Competitors
  • Table 163. Company Basic Information, Sales Area and Its Competitors
  • Table 164. Company Basic Information, Sales Area and Its Competitors
  • Table 165. Company Basic Information, Sales Area and Its Competitors
  • Table 166. Company Basic Information, Sales Area and Its Competitors
  • Table 167. Company Basic Information, Sales Area and Its Competitors
  • Table 168. Company Basic Information, Sales Area and Its Competitors
  • Table 169. Company Basic Information, Sales Area and Its Competitors
  • Table 170. Company Basic Information, Sales Area and Its Competitors
  • Table 171. Company Basic Information, Sales Area and Its Competitors
  • Table 172. Company Basic Information, Sales Area and Its Competitors
  • Table 173. Company Basic Information, Sales Area and Its Competitors
  • Table 174. Antimicrobial Susceptibility Testing: by Type(USD Million)
  • Table 175. Antimicrobial Susceptibility Testing Antibacterial Susceptibility Testing , by Region USD Million (2023-2028)
  • Table 176. Antimicrobial Susceptibility Testing Antifungal Susceptibility Testing , by Region USD Million (2023-2028)
  • Table 177. Antimicrobial Susceptibility Testing Antiparasitic Susceptibility Testing , by Region USD Million (2023-2028)
  • Table 178. Antimicrobial Susceptibility Testing Other Susceptibility Testing , by Region USD Million (2023-2028)
  • Table 179. Antimicrobial Susceptibility Testing: by Application(USD Million)
  • Table 180. Antimicrobial Susceptibility Testing Clinical Diagnostics , by Region USD Million (2023-2028)
  • Table 181. Antimicrobial Susceptibility Testing Drug Discovery and Development , by Region USD Million (2023-2028)
  • Table 182. Antimicrobial Susceptibility Testing Epidemiology , by Region USD Million (2023-2028)
  • Table 183. Antimicrobial Susceptibility Testing Other Applications , by Region USD Million (2023-2028)
  • Table 184. Antimicrobial Susceptibility Testing: by Product(USD Million)
  • Table 185. Antimicrobial Susceptibility Testing Manual Antimicrobial Susceptibility Testing Products , by Region USD Million (2023-2028)
  • Table 186. Antimicrobial Susceptibility Testing Automated Laboratory Instruments , by Region USD Million (2023-2028)
  • Table 187. Antimicrobial Susceptibility Testing Culture and Growth Media , by Region USD Million (2023-2028)
  • Table 188. Antimicrobial Susceptibility Testing Consumables , by Region USD Million (2023-2028)
  • Table 189. Antimicrobial Susceptibility Testing: by Method(USD Million)
  • Table 190. Antimicrobial Susceptibility Testing Disk Diffusion , by Region USD Million (2023-2028)
  • Table 191. Antimicrobial Susceptibility Testing Automated Ast , by Region USD Million (2023-2028)
  • Table 192. Antimicrobial Susceptibility Testing Genotypic Methods , by Region USD Million (2023-2028)
  • Table 193. Antimicrobial Susceptibility Testing Dilution , by Region USD Million (2023-2028)
  • Table 194. Antimicrobial Susceptibility Testing Etest , by Region USD Million (2023-2028)
  • Table 195. Antimicrobial Susceptibility Testing: by End User(USD Million)
  • Table 196. Antimicrobial Susceptibility Testing Diagnostic Centers and Hospitals , by Region USD Million (2023-2028)
  • Table 197. Antimicrobial Susceptibility Testing Pharmaceutical and Biotechnology Companies , by Region USD Million (2023-2028)
  • Table 198. Antimicrobial Susceptibility Testing Contract Research Organizations (CROs) , by Region USD Million (2023-2028)
  • Table 199. Antimicrobial Susceptibility Testing Research and Academic Institutes , by Region USD Million (2023-2028)
  • Table 200. South America Antimicrobial Susceptibility Testing, by Country USD Million (2023-2028)
  • Table 201. South America Antimicrobial Susceptibility Testing, by Type USD Million (2023-2028)
  • Table 202. South America Antimicrobial Susceptibility Testing, by Application USD Million (2023-2028)
  • Table 203. South America Antimicrobial Susceptibility Testing, by Product USD Million (2023-2028)
  • Table 204. South America Antimicrobial Susceptibility Testing, by Method USD Million (2023-2028)
  • Table 205. South America Antimicrobial Susceptibility Testing, by End User USD Million (2023-2028)
  • Table 206. Brazil Antimicrobial Susceptibility Testing, by Type USD Million (2023-2028)
  • Table 207. Brazil Antimicrobial Susceptibility Testing, by Application USD Million (2023-2028)
  • Table 208. Brazil Antimicrobial Susceptibility Testing, by Product USD Million (2023-2028)
  • Table 209. Brazil Antimicrobial Susceptibility Testing, by Method USD Million (2023-2028)
  • Table 210. Brazil Antimicrobial Susceptibility Testing, by End User USD Million (2023-2028)
  • Table 211. Argentina Antimicrobial Susceptibility Testing, by Type USD Million (2023-2028)
  • Table 212. Argentina Antimicrobial Susceptibility Testing, by Application USD Million (2023-2028)
  • Table 213. Argentina Antimicrobial Susceptibility Testing, by Product USD Million (2023-2028)
  • Table 214. Argentina Antimicrobial Susceptibility Testing, by Method USD Million (2023-2028)
  • Table 215. Argentina Antimicrobial Susceptibility Testing, by End User USD Million (2023-2028)
  • Table 216. Rest of South America Antimicrobial Susceptibility Testing, by Type USD Million (2023-2028)
  • Table 217. Rest of South America Antimicrobial Susceptibility Testing, by Application USD Million (2023-2028)
  • Table 218. Rest of South America Antimicrobial Susceptibility Testing, by Product USD Million (2023-2028)
  • Table 219. Rest of South America Antimicrobial Susceptibility Testing, by Method USD Million (2023-2028)
  • Table 220. Rest of South America Antimicrobial Susceptibility Testing, by End User USD Million (2023-2028)
  • Table 221. Asia Pacific Antimicrobial Susceptibility Testing, by Country USD Million (2023-2028)
  • Table 222. Asia Pacific Antimicrobial Susceptibility Testing, by Type USD Million (2023-2028)
  • Table 223. Asia Pacific Antimicrobial Susceptibility Testing, by Application USD Million (2023-2028)
  • Table 224. Asia Pacific Antimicrobial Susceptibility Testing, by Product USD Million (2023-2028)
  • Table 225. Asia Pacific Antimicrobial Susceptibility Testing, by Method USD Million (2023-2028)
  • Table 226. Asia Pacific Antimicrobial Susceptibility Testing, by End User USD Million (2023-2028)
  • Table 227. China Antimicrobial Susceptibility Testing, by Type USD Million (2023-2028)
  • Table 228. China Antimicrobial Susceptibility Testing, by Application USD Million (2023-2028)
  • Table 229. China Antimicrobial Susceptibility Testing, by Product USD Million (2023-2028)
  • Table 230. China Antimicrobial Susceptibility Testing, by Method USD Million (2023-2028)
  • Table 231. China Antimicrobial Susceptibility Testing, by End User USD Million (2023-2028)
  • Table 232. Japan Antimicrobial Susceptibility Testing, by Type USD Million (2023-2028)
  • Table 233. Japan Antimicrobial Susceptibility Testing, by Application USD Million (2023-2028)
  • Table 234. Japan Antimicrobial Susceptibility Testing, by Product USD Million (2023-2028)
  • Table 235. Japan Antimicrobial Susceptibility Testing, by Method USD Million (2023-2028)
  • Table 236. Japan Antimicrobial Susceptibility Testing, by End User USD Million (2023-2028)
  • Table 237. India Antimicrobial Susceptibility Testing, by Type USD Million (2023-2028)
  • Table 238. India Antimicrobial Susceptibility Testing, by Application USD Million (2023-2028)
  • Table 239. India Antimicrobial Susceptibility Testing, by Product USD Million (2023-2028)
  • Table 240. India Antimicrobial Susceptibility Testing, by Method USD Million (2023-2028)
  • Table 241. India Antimicrobial Susceptibility Testing, by End User USD Million (2023-2028)
  • Table 242. South Korea Antimicrobial Susceptibility Testing, by Type USD Million (2023-2028)
  • Table 243. South Korea Antimicrobial Susceptibility Testing, by Application USD Million (2023-2028)
  • Table 244. South Korea Antimicrobial Susceptibility Testing, by Product USD Million (2023-2028)
  • Table 245. South Korea Antimicrobial Susceptibility Testing, by Method USD Million (2023-2028)
  • Table 246. South Korea Antimicrobial Susceptibility Testing, by End User USD Million (2023-2028)
  • Table 247. Taiwan Antimicrobial Susceptibility Testing, by Type USD Million (2023-2028)
  • Table 248. Taiwan Antimicrobial Susceptibility Testing, by Application USD Million (2023-2028)
  • Table 249. Taiwan Antimicrobial Susceptibility Testing, by Product USD Million (2023-2028)
  • Table 250. Taiwan Antimicrobial Susceptibility Testing, by Method USD Million (2023-2028)
  • Table 251. Taiwan Antimicrobial Susceptibility Testing, by End User USD Million (2023-2028)
  • Table 252. Australia Antimicrobial Susceptibility Testing, by Type USD Million (2023-2028)
  • Table 253. Australia Antimicrobial Susceptibility Testing, by Application USD Million (2023-2028)
  • Table 254. Australia Antimicrobial Susceptibility Testing, by Product USD Million (2023-2028)
  • Table 255. Australia Antimicrobial Susceptibility Testing, by Method USD Million (2023-2028)
  • Table 256. Australia Antimicrobial Susceptibility Testing, by End User USD Million (2023-2028)
  • Table 257. Rest of Asia-Pacific Antimicrobial Susceptibility Testing, by Type USD Million (2023-2028)
  • Table 258. Rest of Asia-Pacific Antimicrobial Susceptibility Testing, by Application USD Million (2023-2028)
  • Table 259. Rest of Asia-Pacific Antimicrobial Susceptibility Testing, by Product USD Million (2023-2028)
  • Table 260. Rest of Asia-Pacific Antimicrobial Susceptibility Testing, by Method USD Million (2023-2028)
  • Table 261. Rest of Asia-Pacific Antimicrobial Susceptibility Testing, by End User USD Million (2023-2028)
  • Table 262. Europe Antimicrobial Susceptibility Testing, by Country USD Million (2023-2028)
  • Table 263. Europe Antimicrobial Susceptibility Testing, by Type USD Million (2023-2028)
  • Table 264. Europe Antimicrobial Susceptibility Testing, by Application USD Million (2023-2028)
  • Table 265. Europe Antimicrobial Susceptibility Testing, by Product USD Million (2023-2028)
  • Table 266. Europe Antimicrobial Susceptibility Testing, by Method USD Million (2023-2028)
  • Table 267. Europe Antimicrobial Susceptibility Testing, by End User USD Million (2023-2028)
  • Table 268. Germany Antimicrobial Susceptibility Testing, by Type USD Million (2023-2028)
  • Table 269. Germany Antimicrobial Susceptibility Testing, by Application USD Million (2023-2028)
  • Table 270. Germany Antimicrobial Susceptibility Testing, by Product USD Million (2023-2028)
  • Table 271. Germany Antimicrobial Susceptibility Testing, by Method USD Million (2023-2028)
  • Table 272. Germany Antimicrobial Susceptibility Testing, by End User USD Million (2023-2028)
  • Table 273. France Antimicrobial Susceptibility Testing, by Type USD Million (2023-2028)
  • Table 274. France Antimicrobial Susceptibility Testing, by Application USD Million (2023-2028)
  • Table 275. France Antimicrobial Susceptibility Testing, by Product USD Million (2023-2028)
  • Table 276. France Antimicrobial Susceptibility Testing, by Method USD Million (2023-2028)
  • Table 277. France Antimicrobial Susceptibility Testing, by End User USD Million (2023-2028)
  • Table 278. Italy Antimicrobial Susceptibility Testing, by Type USD Million (2023-2028)
  • Table 279. Italy Antimicrobial Susceptibility Testing, by Application USD Million (2023-2028)
  • Table 280. Italy Antimicrobial Susceptibility Testing, by Product USD Million (2023-2028)
  • Table 281. Italy Antimicrobial Susceptibility Testing, by Method USD Million (2023-2028)
  • Table 282. Italy Antimicrobial Susceptibility Testing, by End User USD Million (2023-2028)
  • Table 283. United Kingdom Antimicrobial Susceptibility Testing, by Type USD Million (2023-2028)
  • Table 284. United Kingdom Antimicrobial Susceptibility Testing, by Application USD Million (2023-2028)
  • Table 285. United Kingdom Antimicrobial Susceptibility Testing, by Product USD Million (2023-2028)
  • Table 286. United Kingdom Antimicrobial Susceptibility Testing, by Method USD Million (2023-2028)
  • Table 287. United Kingdom Antimicrobial Susceptibility Testing, by End User USD Million (2023-2028)
  • Table 288. Netherlands Antimicrobial Susceptibility Testing, by Type USD Million (2023-2028)
  • Table 289. Netherlands Antimicrobial Susceptibility Testing, by Application USD Million (2023-2028)
  • Table 290. Netherlands Antimicrobial Susceptibility Testing, by Product USD Million (2023-2028)
  • Table 291. Netherlands Antimicrobial Susceptibility Testing, by Method USD Million (2023-2028)
  • Table 292. Netherlands Antimicrobial Susceptibility Testing, by End User USD Million (2023-2028)
  • Table 293. Rest of Europe Antimicrobial Susceptibility Testing, by Type USD Million (2023-2028)
  • Table 294. Rest of Europe Antimicrobial Susceptibility Testing, by Application USD Million (2023-2028)
  • Table 295. Rest of Europe Antimicrobial Susceptibility Testing, by Product USD Million (2023-2028)
  • Table 296. Rest of Europe Antimicrobial Susceptibility Testing, by Method USD Million (2023-2028)
  • Table 297. Rest of Europe Antimicrobial Susceptibility Testing, by End User USD Million (2023-2028)
  • Table 298. MEA Antimicrobial Susceptibility Testing, by Country USD Million (2023-2028)
  • Table 299. MEA Antimicrobial Susceptibility Testing, by Type USD Million (2023-2028)
  • Table 300. MEA Antimicrobial Susceptibility Testing, by Application USD Million (2023-2028)
  • Table 301. MEA Antimicrobial Susceptibility Testing, by Product USD Million (2023-2028)
  • Table 302. MEA Antimicrobial Susceptibility Testing, by Method USD Million (2023-2028)
  • Table 303. MEA Antimicrobial Susceptibility Testing, by End User USD Million (2023-2028)
  • Table 304. Middle East Antimicrobial Susceptibility Testing, by Type USD Million (2023-2028)
  • Table 305. Middle East Antimicrobial Susceptibility Testing, by Application USD Million (2023-2028)
  • Table 306. Middle East Antimicrobial Susceptibility Testing, by Product USD Million (2023-2028)
  • Table 307. Middle East Antimicrobial Susceptibility Testing, by Method USD Million (2023-2028)
  • Table 308. Middle East Antimicrobial Susceptibility Testing, by End User USD Million (2023-2028)
  • Table 309. Africa Antimicrobial Susceptibility Testing, by Type USD Million (2023-2028)
  • Table 310. Africa Antimicrobial Susceptibility Testing, by Application USD Million (2023-2028)
  • Table 311. Africa Antimicrobial Susceptibility Testing, by Product USD Million (2023-2028)
  • Table 312. Africa Antimicrobial Susceptibility Testing, by Method USD Million (2023-2028)
  • Table 313. Africa Antimicrobial Susceptibility Testing, by End User USD Million (2023-2028)
  • Table 314. North America Antimicrobial Susceptibility Testing, by Country USD Million (2023-2028)
  • Table 315. North America Antimicrobial Susceptibility Testing, by Type USD Million (2023-2028)
  • Table 316. North America Antimicrobial Susceptibility Testing, by Application USD Million (2023-2028)
  • Table 317. North America Antimicrobial Susceptibility Testing, by Product USD Million (2023-2028)
  • Table 318. North America Antimicrobial Susceptibility Testing, by Method USD Million (2023-2028)
  • Table 319. North America Antimicrobial Susceptibility Testing, by End User USD Million (2023-2028)
  • Table 320. United States Antimicrobial Susceptibility Testing, by Type USD Million (2023-2028)
  • Table 321. United States Antimicrobial Susceptibility Testing, by Application USD Million (2023-2028)
  • Table 322. United States Antimicrobial Susceptibility Testing, by Product USD Million (2023-2028)
  • Table 323. United States Antimicrobial Susceptibility Testing, by Method USD Million (2023-2028)
  • Table 324. United States Antimicrobial Susceptibility Testing, by End User USD Million (2023-2028)
  • Table 325. Canada Antimicrobial Susceptibility Testing, by Type USD Million (2023-2028)
  • Table 326. Canada Antimicrobial Susceptibility Testing, by Application USD Million (2023-2028)
  • Table 327. Canada Antimicrobial Susceptibility Testing, by Product USD Million (2023-2028)
  • Table 328. Canada Antimicrobial Susceptibility Testing, by Method USD Million (2023-2028)
  • Table 329. Canada Antimicrobial Susceptibility Testing, by End User USD Million (2023-2028)
  • Table 330. Mexico Antimicrobial Susceptibility Testing, by Type USD Million (2023-2028)
  • Table 331. Mexico Antimicrobial Susceptibility Testing, by Application USD Million (2023-2028)
  • Table 332. Mexico Antimicrobial Susceptibility Testing, by Product USD Million (2023-2028)
  • Table 333. Mexico Antimicrobial Susceptibility Testing, by Method USD Million (2023-2028)
  • Table 334. Mexico Antimicrobial Susceptibility Testing, by End User USD Million (2023-2028)
  • Table 335. Research Programs/Design for This Report
  • Table 336. Key Data Information from Secondary Sources
  • Table 337. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Antimicrobial Susceptibility Testing: by Type USD Million (2017-2022)
  • Figure 5. Global Antimicrobial Susceptibility Testing: by Application USD Million (2017-2022)
  • Figure 6. Global Antimicrobial Susceptibility Testing: by Product USD Million (2017-2022)
  • Figure 7. Global Antimicrobial Susceptibility Testing: by Method USD Million (2017-2022)
  • Figure 8. Global Antimicrobial Susceptibility Testing: by End User USD Million (2017-2022)
  • Figure 9. South America Antimicrobial Susceptibility Testing Share (%), by Country
  • Figure 10. Asia Pacific Antimicrobial Susceptibility Testing Share (%), by Country
  • Figure 11. Europe Antimicrobial Susceptibility Testing Share (%), by Country
  • Figure 12. MEA Antimicrobial Susceptibility Testing Share (%), by Country
  • Figure 13. North America Antimicrobial Susceptibility Testing Share (%), by Country
  • Figure 14. Global Antimicrobial Susceptibility Testing share by Players 2022 (%)
  • Figure 15. Global Antimicrobial Susceptibility Testing share by Players (Top 3) 2022(%)
  • Figure 16. Global Antimicrobial Susceptibility Testing share by Players (Top 5) 2022(%)
  • Figure 17. BCG Matrix for key Companies
  • Figure 18. Biomérieux (France) Revenue, Net Income and Gross profit
  • Figure 19. Biomérieux (France) Revenue: by Geography 2022
  • Figure 20. Danaher (United States) Revenue, Net Income and Gross profit
  • Figure 21. Danaher (United States) Revenue: by Geography 2022
  • Figure 22. BD (United States) Revenue, Net Income and Gross profit
  • Figure 23. BD (United States) Revenue: by Geography 2022
  • Figure 24. Thermo Fisher (United States) Revenue, Net Income and Gross profit
  • Figure 25. Thermo Fisher (United States) Revenue: by Geography 2022
  • Figure 26. Hi-Media (India) Revenue, Net Income and Gross profit
  • Figure 27. Hi-Media (India) Revenue: by Geography 2022
  • Figure 28. Bio-Rad (United States) Revenue, Net Income and Gross profit
  • Figure 29. Bio-Rad (United States) Revenue: by Geography 2022
  • Figure 30. Merlin (Germany) Revenue, Net Income and Gross profit
  • Figure 31. Merlin (Germany) Revenue: by Geography 2022
  • Figure 32. Liofilchem (Italy) Revenue, Net Income and Gross profit
  • Figure 33. Liofilchem (Italy) Revenue: by Geography 2022
  • Figure 34. Accelerate (United States) Revenue, Net Income and Gross profit
  • Figure 35. Accelerate (United States) Revenue: by Geography 2022
  • Figure 36. Alifax (Italy) Revenue, Net Income and Gross profit
  • Figure 37. Alifax (Italy) Revenue: by Geography 2022
  • Figure 38. Creative Diagnostics (United States) Revenue, Net Income and Gross profit
  • Figure 39. Creative Diagnostics (United States) Revenue: by Geography 2022
  • Figure 40. Merck Group (Germany) Revenue, Net Income and Gross profit
  • Figure 41. Merck Group (Germany) Revenue: by Geography 2022
  • Figure 42. Global Antimicrobial Susceptibility Testing: by Type USD Million (2023-2028)
  • Figure 43. Global Antimicrobial Susceptibility Testing: by Application USD Million (2023-2028)
  • Figure 44. Global Antimicrobial Susceptibility Testing: by Product USD Million (2023-2028)
  • Figure 45. Global Antimicrobial Susceptibility Testing: by Method USD Million (2023-2028)
  • Figure 46. Global Antimicrobial Susceptibility Testing: by End User USD Million (2023-2028)
  • Figure 47. South America Antimicrobial Susceptibility Testing Share (%), by Country
  • Figure 48. Asia Pacific Antimicrobial Susceptibility Testing Share (%), by Country
  • Figure 49. Europe Antimicrobial Susceptibility Testing Share (%), by Country
  • Figure 50. MEA Antimicrobial Susceptibility Testing Share (%), by Country
  • Figure 51. North America Antimicrobial Susceptibility Testing Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Biomérieux (France)
  • Danaher (United States)
  • BD (United States)
  • Thermo Fisher (United States)
  • Hi-Media (India)
  • Bio-Rad (United States)
  • Merlin (Germany)
  • Liofilchem (Italy)
  • Accelerate (United States)
  • Alifax (Italy)
  • Creative Diagnostics (United States)
  • Merck Group (Germany)
Additional players considered in the study are as follows:
Bioanalyse (Turkey) , Synbiosis (United Kingdom) , Zhuhai Dl Biotech (China)
Select User Access Type

Key Highlights of Report


May 2023 247 Pages 57 Tables Base Year: 2022 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Antimicrobial Susceptibility Testing Market Quantitative research analysis
Global Antimicrobial Susceptibility Testing Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

"Availability of Automated Antimicrobial Susceptibility Testing Systems" is seen as one of major influencing trends for Antimicrobial Susceptibility Testing Market during projected period 2022-2028.
The Concentration Rate of Global Antimicrobial Susceptibility Testing market is highlighted using HHI Index.
United States Players will contribute the maximum growth of Global Antimicrobial Susceptibility Testing market throughout the predicted period.

Know More About Global Antimicrobial Susceptibility Testing Market Report?

Have a Query? Click Here

Other Related Reports

Peptides Comprehensive Study by Type (Custom (Standard , Quant , Cyclic Custom , Others), Catalog (Neuroscience, Cardiovascular, Diabetes, Others)), Application (Commercial, Academic Research, Therap...
$ 3450
DNA and Gene Chip Comprehensive Study by Type (Oligonucleotide Based Chips {Photolithographic Oligonucleotide Chips, Inkjet Print Technology Generated Oligonucleotide Chips}, CDNA Chips {Mechanical M...
$ 3750
Extremity Tissue Expander Comprehensive Study by Type (Upper extremities, Lower extremities), Application (Breast reconstruction, Scalp reconstruction, Oral and maxillofacial reconstruction, Paediatr...
$ 3650
Antibiotic Resistance Comprehensive Study by Disease (Complicated Urinary Tract Infection {cUTI}, Complicated Intra-Abdominal Infections {cIAI}, Blood Stream Infections {BSI}, Clostridium difficile i...
$ 3750
BioPharma Buffers Comprehensive Study by Type (Phosphates, Acetates, TRIS, Others), Application (Research Institution, Pharmaceutical Industry, Others), Distribution Channel (Online, Offline), Packag...
$ 3450
Protein Labeling Comprehensive Study by Type (Reagents, Kits, Services), Application (Cell-based Assays, Fluorescence Microscopy, Immunological Techniques, Mass Spectrometry, Protein Microarray), Pro...
$ 3750